National Institutes of Health to Consider Exclusive License for Insulin Producing Cells

Summary

The National Institutes of Health is seeking to grant an exclusive license worldwide to practice a patent for insulin producing cells differentiated by GLP-1 and Exendin-4, developed by Amylin Pharmaceuticals, Inc.